NuCana plc
NCNANasdaq
$1.32
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↓ -86.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
NuCana plc engages in the development of products for the treatment of cancer. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil.
- CEO
- Hugh S. Griffith
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Website
- nucana.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.